anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: SODIUM CHLORIDE
Trial phase: Phase 1 | Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 27
Group description: Patients randomized to receive 3 doses of normal saline control.

Normal saline: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.

.
Eligibility criteria:
Inclusion Criteria:

Neonates (<30 days) undergoing cardiac surgery with cardiopulmonary bypass will be enrolled.

Inclusion criteria include patients with:

single ventricle: hypoplastic left heart syndrome or variant undergoing Norwood Stage I or Sano palliation (SV group);
patients with D-transposition of the great vessels with or without ventricular septal defect (VSD) undergoing arterial switch operation with VSD closure if needed (ASO group); and
patients with interrupted or hypoplastic aortic arch with intracardiac defects (VSD, ASD, or subaortic stenosis) who are undergoing complete 2- ventricle repair including aortic arch advancement(AAA group), any other 2 ventricle lesion scheduled for complex anatomic repair.

Exclusion Criteria:

Gestational age less than 35 weeks at birth
Weight less than 2 kg
Known recognizable dysmorphic syndrome
Surgery not requiring cardiopulmonary bypass
Preoperative cardiac arrest requiring chest compressions for greater than 3 minutes
Inability to enroll the patient greater than 12 hours preoperatively
Aortic crossclamping is not used
CPB times are anticipated to be less than 60 minutes
A nadir temperature on bypass greater than 25° C is planned.
Presence of known contraindications to EPO administration-sustained systolic blood pressure >100, hemoglobin .18 g/dL, known allergy to EPO or one of its components
Platelet count >600,000 per dL, INR <0.8.
Maternal history of major vascular thrombosis, or multiple fetal loss (3 or more spontaneous abortions).
Intervention: Melatonin
Trial phase: Phase 3
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: 20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Patients with solid gastrointestinal tumors or lung cancer patients referred to palliative care and a 5% or more involuntary weight loss within the last 6 months with anorexia (>3 on visual analog scale such as ESAS)
Greater than or equal to 18 years of age
Karnofsky score of 40 or higher
Patient has the ability to maintain oral food intake during the study period
If patients who have persistent anorexia/cachexia and are currently taking Megace, corticosteroids, non-steroidal anti-inflammatories (NSAID's), or thalidomide, they should be on the medication at least 2 weeks prior to study inclusion
Ability to sign informed consent and understand study procedures
Patient can continue all medications including complementary therapies or antineoplastic therapy while on-study other than melatonin if they have been on stable dose for at least 2 weeks
Negative pregnancy testing in women with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
Patients who cannot take Megace because of past history or elevated risk of DVT, adrenal insufficiency, impotence, hyperglycemia, CHF, menorrhagia, etc.
Patients who have persistent anorexia/cachexia after treatment with Megace has failed

Exclusion Criteria:

Patients who have dementia or delirium on entry into study as determined by the palliative care specialist using DSM-IV-criteria
Patients who are currently taking melatonin
Inability to take oral food during the study period
Unstable secondary cachexia caused by nausea, diarrhea, taste abnormalities, mucositis, constipation, dysphagia, or clinical depression prior to study inclusion. These symptoms should be resolved or stable for >/= 2 weeks at the time of inclusion into study as determined by the Palliative Care Specialist.
Inability to sign informed consent or understand study procedures
Karnofsky score of < 40
Patients < 18 years of age
Patients with </= 5% involuntary weight loss within the last 6 months and anorexia of < 3 on ESAS
Patients who are on complementary therapies containing melatonin or on medications for < 2 weeks and not on stable dose
Patients who have a cortisol level of </= 4.3 mg/dL at baseline will be excluded, unless they are on replacement corticosteroids.
Patients with a TSH of </= 0.50 or >/= 10 mcL/mL at baseline will be excluded
Pregnant females or females who are lactating/nursing
Intervention: VALACYCLOVIR
Trial phase: Phase 2
ATC code: J05AB11
SMILES: CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
Eligibility criteria:
Inclusion Criteria:

Both genders between the ages of 18-50 years
Schizophrenia or schizoaffective disorder as defined in DSM-IV
Duration of illness 10 years or less
On a stable dose of an antipsychotic medication for at least a month
Should score 4 or more on at least one of the subscales of PANSS
Positive for HSV1
Written informed consent

Exclusion Criteria:

Substance abuse in the last month/dependence 6 months prior to the study
History of, or current medical/neurological illnesses which affects CNS function e.g., epilepsy, head injury with prolonged loss of consciousness
Pregnancy
History of immune disorders, HIV infection or currently receiving immunosuppressants
Subjects on regular antiviral therapy
History of hypersensitivity to Valacyclovir
Mental retardation as defined in DSM-IV
Intervention: Testosterone
Trial phase: Phase 2
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Three subjects received testosterone gel

AndroGel: Androgel 1%, 10g daily
Eligibility criteria:
Inclusion Criteria:

Prostate cancer
Patient must have received primary definitive local therapy to the prostate (surgery and/or radiotherapy)
Patient was surgically or pharmacologically castrated at least 6 months prior to starting the study
Patient must have had a previous trial of anti-androgen therapy
Patient must have a rising PSA
No evidence of distant metastatic disease
ECOG performance status < 2
Age >18 years
Patients must have normal hepatic function

Exclusion Criteria:

Patients with a history of any previous cytotoxic therapy or radionuclide therapy (such as rhenium, strontium, or samarium)
Patients may not be receiving any other investigational agents
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Patients receiving renal dialysis
Patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization will be excluded
Patients who have known hypersensitivity to any of the AndroGel ingredients, including testosterone that is chemically synthesized from soy
Intervention: Lincomycin
Trial phase: Phase 3
ATC code: J01FF02
SMILES: [H][C@@]1(C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)C[C@@H](CCC)CN1C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 376
Group description: 50 mg and 100 mg tablets of lacosamide up to 800 mg/day as twice day (BID) dosing throughout the trial (flexible dosing)
Eligibility criteria:
Inclusion Criteria:

diagnosis of Epilepsy
completion of double blind trial

Exclusion Criteria:

taking other investigational drug than Lacosamide
meeting withdrawal criteria from double blind trial
Intervention: Olanzapine
Trial phase: Not Applicable
ATC code: N05AH03 | N05AH53
SMILES: Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Participants with schizophrenia were randomized to olanzapine.
Eligibility criteria:
Inclusion Criteria:

Aged 18-60 years
Patients: otherwise healthy and meets DSM-IV criteria for schizophrenia or schizoaffective disorder, any type, treated with haloperidol, olanzapine, clozapine, quetiapine, ziprasidone, aripiprazole, or risperidone for at least 3 months
Controls: healthy
Able to give informed consent
No antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.

Exclusion Criteria:

Axis I psychiatric disorder criteria met in self except for substance use disorders as below
Patients and controls: meets DSM-IV criteria for the diagnoses of substance abuse within the past 3 months
Involuntary legal status (as per Missouri law)
The presence of any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, symptomatic type 2 diabetes mellitus (see below), pregnancy, endocrine disease, coagulopathy, clinically significant anemia, that would preclude blood sampling (as determined by the PI) or acute infection;
Patients taking more than one atypical antipsychotic medication;
Subjects taking certain prescription medications (as determined by PI on a case by case basis).
Intervention: Risperidone
Trial phase: Not Applicable
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Patients with schizophrenia were randomized to risperidone.
Eligibility criteria:
Inclusion Criteria:

Aged 18-60 years
Patients: otherwise healthy and meets DSM-IV criteria for schizophrenia or schizoaffective disorder, any type, treated with haloperidol, olanzapine, clozapine, quetiapine, ziprasidone, aripiprazole, or risperidone for at least 3 months
Controls: healthy
Able to give informed consent
No antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.

Exclusion Criteria:

Axis I psychiatric disorder criteria met in self except for substance use disorders as below
Patients and controls: meets DSM-IV criteria for the diagnoses of substance abuse within the past 3 months
Involuntary legal status (as per Missouri law)
The presence of any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, symptomatic type 2 diabetes mellitus (see below), pregnancy, endocrine disease, coagulopathy, clinically significant anemia, that would preclude blood sampling (as determined by the PI) or acute infection;
Patients taking more than one atypical antipsychotic medication;
Subjects taking certain prescription medications (as determined by PI on a case by case basis).
Intervention: Quetiapine
Trial phase: Not Applicable
ATC code: N05AH04
SMILES: OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Participants with schizophrenia were randomized to quetiapine.
Eligibility criteria:
Inclusion Criteria:

Aged 18-60 years
Patients: otherwise healthy and meets DSM-IV criteria for schizophrenia or schizoaffective disorder, any type, treated with haloperidol, olanzapine, clozapine, quetiapine, ziprasidone, aripiprazole, or risperidone for at least 3 months
Controls: healthy
Able to give informed consent
No antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.

Exclusion Criteria:

Axis I psychiatric disorder criteria met in self except for substance use disorders as below
Patients and controls: meets DSM-IV criteria for the diagnoses of substance abuse within the past 3 months
Involuntary legal status (as per Missouri law)
The presence of any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, symptomatic type 2 diabetes mellitus (see below), pregnancy, endocrine disease, coagulopathy, clinically significant anemia, that would preclude blood sampling (as determined by the PI) or acute infection;
Patients taking more than one atypical antipsychotic medication;
Subjects taking certain prescription medications (as determined by PI on a case by case basis).
Intervention: Ziprasidone
Trial phase: Not Applicable
ATC code: N05AE04
SMILES: O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Participants with schizophrenia were randomized to ziprasidone.
Eligibility criteria:
Inclusion Criteria:

Aged 18-60 years
Patients: otherwise healthy and meets DSM-IV criteria for schizophrenia or schizoaffective disorder, any type, treated with haloperidol, olanzapine, clozapine, quetiapine, ziprasidone, aripiprazole, or risperidone for at least 3 months
Controls: healthy
Able to give informed consent
No antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.

Exclusion Criteria:

Axis I psychiatric disorder criteria met in self except for substance use disorders as below
Patients and controls: meets DSM-IV criteria for the diagnoses of substance abuse within the past 3 months
Involuntary legal status (as per Missouri law)
The presence of any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, symptomatic type 2 diabetes mellitus (see below), pregnancy, endocrine disease, coagulopathy, clinically significant anemia, that would preclude blood sampling (as determined by the PI) or acute infection;
Patients taking more than one atypical antipsychotic medication;
Subjects taking certain prescription medications (as determined by PI on a case by case basis).
Intervention: EXENATIDE
Trial phase: Phase 3
ATC code: A10BJ01
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks. Assessed as negative for antibodies to exenatide throughout the study.
Eligibility criteria:
Inclusion Criteria:

Diagnosed with type 2 diabetes.
Have been exposed to exenatide for at least 3 months in previous Amylin/Lilly Studies H8O-MC-GWAO, H8O-MC-GWAP, H8O-MC-GWAT, or H8O-MC-GWBA.
Have interrupted exenatide treatment for a period of at least 2 months.
HbA1c of ≤10.5%.

Exclusion Criteria:

Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Have previously completed or withdrawn from this study.
Have taken marketed exenatide (Byetta) during the interim period between studies GWAO, GWAP, GWAT, or GWBA and the current study.
Used drugs for weight loss (for example, Xenical® [orlistat], Meridia® [sibutramine], Acutrim® [phenylpropanolamine], Accomplia® [rimonabant], or similar over-the-counter medications) within 3 months of screening.
Are currently treated with any of the following excluded medications: Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.
Use insulin with daily dosage exceeding 1 U/kg.
Intervention: EXENATIDE
Trial phase: Phase 3
ATC code: A10BJ01
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: 5mcg exenatide twice daily for 4 weeks, and then 10mcg exenatide twice daily for the remaining 8 weeks of the study.
Eligibility criteria:
Inclusion Criteria:

Diagnosed with type 2 diabetes.
Treated with metformin and/or a thiazolidinedione.
HbA1c between 6.5% and 9.5%, inclusive.
Body Mass Index (BMI) > 25 kg/m^2 and < 40 kg/m^2.

Exclusion Criteria:

Have previously received exenatide or glucagon-like peptide-1 analogs.
Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
Receiving beta blockers.
Receiving treatment with a drug directly affecting gastrointestinal motility, including but not limited to Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.
Have received treatment with systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route within 6 weeks of screening, or are regularly treated with potent, inhaled intranasal steroids that are known to have a high rate of systemic absorption or bronchodilators.
Have been treated with drugs that promote weight loss (for example, Adipex® [phentermine], Acomplia® [rimonabant], Xenical® [orlistat], Meridia® [sibutramine], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: *Insulin; *Alpha-glucosidase inhibitors (for example, Glyset® [miglitol] or Precose® [acarbose]); *Meglitinides (for example, Prandin® [repaglinide] or Starlix® [nateglinide]); *Sulfonylureas (for example, Glucotrol® [glipizide] or Micronase® [glyburide]); *Dipeptidyl peptidase IV (DPP-IV) inhibitors (for example, Januvia™ [sitagliptin])
Have donated blood within 60 days of screening.
Intervention: CID 12303048
Trial phase: Phase 2 | Phase 3
ATC code: S03AA04
SMILES: NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.O=C(O)C(O)C(O)C(O)C(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Chlorhexidine gluconate antimicrobial transparent adhesive dressing
Eligibility criteria:
Inclusion Criteria:

Males or Females over 18 years of age
Patients with an existing, or newly inserted, central venous catheter
Patients who require the catheter for at least 3 days

Exclusion Criteria:

Sensitivity to chlorhexidine
Intervention: Orlistat
Trial phase: Phase 4
ATC code: A08AB01
SMILES: CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 79
Group description: Xenical + behavioral intervention

Xenical + behavioral intervention : 120 mg three times a day; Behavioral weight loss in Spanish
Eligibility criteria:
Inclusion Criteria:

Monolingual Spanish Speaking
Obese (BMI >= 30)

Exclusion Criteria:

Pregnancy
Current cardiac disease
Serious neurologic illnesses
Intervention: Vaniprevir
Trial phase: Phase 1
SMILES: [H][C@@]1(C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2CC)C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Patients received an oral dose of 25mg MK7009 twice a day (b.i.d.) for 7 days and on the morning of Day 8.
Eligibility criteria:
Inclusion Criteria:

Subject is a man or a woman aged 18 to 55 years of age.
Subject has chronic Hepatitis C
Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period

Exclusion Criteria:

Patient has evidence of advanced liver disease.
Patient has human immunodeficiency virus (HIV)
Patient has Hepatitis B
Intervention: Vaniprevir
Trial phase: Phase 1
SMILES: [H][C@@]1(C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2CC)C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Patients received an oral dose of 75mg MK7009 twice a day (b.i.d.) for 7 days and on the morning of Day 8.
Eligibility criteria:
Inclusion Criteria:

Subject is a man or a woman aged 18 to 55 years of age.
Subject has chronic Hepatitis C
Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period

Exclusion Criteria:

Patient has evidence of advanced liver disease.
Patient has human immunodeficiency virus (HIV)
Patient has Hepatitis B
Intervention: Vaniprevir
Trial phase: Phase 1
SMILES: [H][C@@]1(C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2CC)C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Patients received an oral dose of 250 mg MK7009 twice a day (b.i.d.) for 7 days and on the morning of Day 8.
Eligibility criteria:
Inclusion Criteria:

Subject is a man or a woman aged 18 to 55 years of age.
Subject has chronic Hepatitis C
Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period

Exclusion Criteria:

Patient has evidence of advanced liver disease.
Patient has human immunodeficiency virus (HIV)
Patient has Hepatitis B
Intervention: Vaniprevir
Trial phase: Phase 1
SMILES: [H][C@@]1(C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2CC)C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Patients received an oral dose of 500 mg MK7009 twice a day (b.i.d.) for 7 days and on the morning of Day 8.
Eligibility criteria:
Inclusion Criteria:

Subject is a man or a woman aged 18 to 55 years of age.
Subject has chronic Hepatitis C
Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period

Exclusion Criteria:

Patient has evidence of advanced liver disease.
Patient has human immunodeficiency virus (HIV)
Patient has Hepatitis B